BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 33196436)

  • 1. Possible candidate population for neoadjuvant chemotherapy in women with advanced ovarian cancer.
    Matsuo K; Matsuzaki S; Nusbaum DJ; Maoz A; Oda K; Klar M; Roman LD; Sood AK
    Gynecol Oncol; 2021 Jan; 160(1):32-39. PubMed ID: 33196436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uptake and Outcomes of Neoadjuvant Chemotherapy Among US Patients With Less Common Epithelial Ovarian Carcinomas.
    Matsuo K; Matsuzaki S; Maeda M; Rau AR; Yoshihara K; Tamura R; Shimada M; Machida H; Mikami M; Klar M; Roman LD; Wright JD; Sood AK; Gershenson DM
    JAMA Netw Open; 2023 Jun; 6(6):e2318602. PubMed ID: 37326992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends in the use of neoadjuvant chemotherapy for low-grade serous ovarian cancer in the United States.
    Silberman JN; Bercow AS; Gockley AA; Eisenhauer EL; Sisodia R; Randall T; Del Carmen MG; Goodman A; Castro CM; Melamed A; Bregar AJ
    Gynecol Oncol; 2023 Aug; 175():60-65. PubMed ID: 37327540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overall Survival Following Neoadjuvant Chemotherapy vs Primary Cytoreductive Surgery in Women With Epithelial Ovarian Cancer: Analysis of the National Cancer Database.
    Rauh-Hain JA; Melamed A; Wright A; Gockley A; Clemmer JT; Schorge JO; Del Carmen MG; Keating NL
    JAMA Oncol; 2017 Jan; 3(1):76-82. PubMed ID: 27892998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer.
    Meyer LA; Cronin AM; Sun CC; Bixel K; Bookman MA; Cristea MC; Griggs JJ; Levenback CF; Burger RA; Mantia-Smaldone G; Matulonis UA; Niland JC; O'Malley DM; Wright AA
    J Clin Oncol; 2016 Nov; 34(32):3854-3863. PubMed ID: 27601552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant chemotherapy in elderly women with ovarian cancer: Rates of use and effectiveness.
    Meyer LA; He W; Sun CC; Zhao H; Wright AA; Suidan RS; Dottino J; Alejandro Rauh-Hain J; Lu KH; Giordano SH
    Gynecol Oncol; 2018 Sep; 150(3):451-459. PubMed ID: 29961559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple Cycles of Neoadjuvant Chemotherapy Associated With Poor Survival in Bulky Stage IIIC and IV Ovarian Cancer.
    Ren Y; Shi T; Jiang R; Yin S; Wang P; Zang R
    Int J Gynecol Cancer; 2015 Oct; 25(8):1398-404. PubMed ID: 26222486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Neoadjuvant Chemotherapy With Overall Survival in Women With Metastatic Endometrial Cancer.
    Tobias CJ; Chen L; Melamed A; St Clair C; Khoury-Collado F; Tergas AI; Hou JY; Hur C; Ananth CV; Neugut AI; Hershman DL; Wright JD
    JAMA Netw Open; 2020 Dec; 3(12):e2028612. PubMed ID: 33295973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of treatment modality on overall survival in women with advanced endometrial cancer: A National Cancer Database analysis.
    Chambers LM; Jia X; Rose PG; AlHilli M
    Gynecol Oncol; 2021 Feb; 160(2):405-412. PubMed ID: 33221023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors associated with delivery of neoadjuvant chemotherapy in women with advanced stage ovarian cancer.
    Hinchcliff E; Melamed A; Bregar A; Diver E; Clemmer J; Del Carmen M; Schorge JO; Alejandro Rauh-Hain J
    Gynecol Oncol; 2018 Jan; 148(1):168-173. PubMed ID: 29128105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of HE4 in advanced-stage, high-grade serous ovarian cancer: Analysis of HE4 kinetics during NACT, predicting surgical outcome and recurrence in comparison to CA125.
    AlSomairi A; Himayda S; Altelmesani A; Lee YJ; Lee JY
    Gynecol Oncol; 2024 Feb; 181():155-161. PubMed ID: 38176127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
    Melamed A; Manning-Geist B; Bregar AJ; Diver EJ; Goodman A; Del Carmen MG; Schorge JO; Rauh-Hain JA
    Gynecol Oncol; 2017 Nov; 147(2):250-256. PubMed ID: 28822556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.
    Gill SE; McGree ME; Weaver AL; Cliby WA; Langstraat CL
    Gynecol Oncol; 2017 Feb; 144(2):266-273. PubMed ID: 27916269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic implications of histological tumor regression (Böhm's score) in patients receiving neoadjuvant chemotherapy for high grade serous tubal & ovarian carcinoma.
    Rajkumar S; Polson A; Nath R; Lane G; Sayasneh A; Jakes A; Begum S; Mehra G
    Gynecol Oncol; 2018 Nov; 151(2):264-268. PubMed ID: 30197060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Similar Overall Survival Using Neoadjuvant Chemotherapy or Primary Debulking Surgery in Patients Aged Over 75 Years with High-Grade Ovarian Cancer.
    Piedimonte S; Kessous R; Laskov I; Abitbol J; Kogan L; Yasmeen A; Salvador S; Lau S; Gotlieb WH
    J Obstet Gynaecol Can; 2020 Nov; 42(11):1339-1345. PubMed ID: 32859533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Upfront debulking surgery versus interval debulking surgery for advanced tubo-ovarian high-grade serous carcinoma and diffuse peritoneal metastases treated with peritonectomy procedures plus HIPEC.
    Biacchi D; Accarpio F; Ansaloni L; Macrì A; Ciardi A; Federici O; Spagnoli A; Cavaliere D; Vaira M; Sapienza P; Sammartino P
    J Surg Oncol; 2019 Dec; 120(7):1208-1219. PubMed ID: 31531879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population-level uptake of neoadjuvant chemotherapy for stage IVB endometrial cancer.
    Jooya ND; Ciccone MA; Brunette LL; Pham HQ; Yessaian AA; Muderspach LI; Roman LD; Matsuo K
    Gynecol Oncol; 2022 Jun; 165(3):428-436. PubMed ID: 35459549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carcinosarcoma of the ovary compared to ovarian high-grade serous carcinoma: impact of optimal cytoreduction and standard adjuvant treatment.
    Yalcin I; Meydanli MM; Turan AT; Taskin S; Sari ME; Gungor T; Akbayir O; Ayhan A
    Int J Clin Oncol; 2018 Apr; 23(2):329-337. PubMed ID: 29143144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO Stage IIIC and IV).
    Glasgow MA; Yu H; Rutherford TJ; Azodi M; Silasi DA; Santin AD; Schwartz PE
    J Surg Oncol; 2013 Feb; 107(2):195-200. PubMed ID: 22648987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Laparoscopy Compared With Laparotomy for Debulking Ovarian Cancer After Neoadjuvant Chemotherapy.
    Melamed A; Nitecki R; Boruta DM; Del Carmen MG; Clark RM; Growdon WB; Goodman A; Schorge JO; Rauh-Hain JA
    Obstet Gynecol; 2017 May; 129(5):861-869. PubMed ID: 28383367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.